UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF250.00. The company’s shares closed yesterday ...

Approval marks first time the agency has approved sale of a nicotine pouch. Referencing the public health standard legally required by the 2009 Family Smoking Prevention and Tobacco Control Act ...

They also can cause people to avoid restaurants and become more isolated from friends FRIDAY, Jan. 31, 2025 (HealthDay News) -- Calorie labels on restaurant menus are harming people with eating ...

Mirikizumab-treated patients achieved statistically significant clinical remission and endoscopic response compared with placebo at week 52. The Food and Drug Administration (FDA) has approved Omvoh ® ...